Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UnitedHealth’s PBM Director Scans The 2009 Pharmaceutical Horizon

Executive Summary

Pharmacy benefit managers face challenges in preparing their health plans for new product launches in 2009, given the increasingly unpredictable competitive environment for pharmaceuticals. A "nervous" FDA, fewer patents expiring for brand name drugs, and high barriers to developing truly better drugs have led to systemic bottlenecks in the availability of new products, and none of these factors are going away anytime soon

You may also be interested in...

Amylin Speculation Intensifies: Byetta LAR May Be Delayed

Comparability studies could mean filing is impossible for first half of 2009, Amylin says.

Novo Nordisk Not Deterred By Regulatory Hurdles For Diabetes Drugs

FDA cardiovascular requirements for Victoza will be met post approval, management predicts.

FDA Puts Off Forest’s Fibromyalgia Drug Milnacipran

For unknown reasons, SSNRI spending weeks in regulatory limbo.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts